elevationoncology.com (ELEV): Rasio rega marang pendapatan
The P/S ratio history of Elevation Oncology (ELEV) reflects the market value dynamics of a company developing unique antibodies to combat specific genetic mutations. captures the magnitude of this parameter. The brand relies on the precision of genetic analysis when developing drugs for rare tumors and is implementing automated systems to analyze large clinical datasets.
Elevation Oncology (ELEV) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Elevation Oncology|ELEV - Rasio utang jangka dawa marang ekuitas|Rasio silihan jangka cendhak marang modal elevationoncology.com|ELEV - Gunggung utang perusahaan|Utang-utang marang aset resik Elevation Oncology|ELEV - Utang jangka dawa perusahaan|Utang jangka cendhak Elevation Oncology|Rasio likuiditas darurat elevationoncology.com
- data bathi lan kelipatan valuasi:
ELEV - Penghasilan resik|Penghasilan resik sing dikarepake Elevation Oncology|ELEV - Rasio rega marang bathi|Rasio prakiraan rega marang bathi Elevation Oncology Inc.|ELEV - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Elevation Oncology|ELEV - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Elevation Oncology|ELEV - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan elevationoncology.com|ELEV - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Elevation Oncology
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis umum perusahaan:ELEV, Elevation Oncology Inc.
A conservative approach to analyzing Elevation Oncology (ELEV) requires comparing market capitalization with annual sales volume to identify asset overvaluation. By analyzing current P/S dynamics, an investor assesses the cost per unit of revenue, which, in the context of inelastic demand for the unique EO-3021 conjugate, confirms the company's strong pricing power and the potential for growth in its investment profile.
Pesaing Elevation Oncology
ONC - Rega marang dodolan|Rasio rega marang pendapatan Halozyme HALO|Revolution Medicines Inc - Rasio rega marang pendapatan|Ascentage - Multiplikator P/S|Rega marang dodolan CG Oncology Therapeutics|URGN (UroGen Pharma Ltd.) - Kapitalisasi marang pendapatan|BCAX (bicara.com) - Rasio rega marang pendapatan|PSNL (Personalis) - Multiplikator P/S|Multiplikator P/S Erasca Inc|Kapitalisasi marang pendapatan DCTH (Delcath)|Kapitalisasi marang volume dodolan YMAB|Multiplikator P/S AURA (Aura Biosciences, Inc.)|Koefisien rega marang pendapatan Candel Therapeutics Inc. (CADL)|ARAY - Rasio rega marang pendapatan|Rega marang dodolan SELLAS Life Sciences|Actuate Therapeutics, Inc (ACTU) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Kapitalisasi marang pendapatan HURA|TARA: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Fate Therapeutics (FATE)|WHWK - Rega marang dodolan|Rasio rega marang pendapatan TScan Therapeutics, Inc. TCRX|CSBR: Rasio kapitalisasi marang pendapatan|XBiotech USA - Multiplikator P/S|CEL-SCI Corporation (CVM) - Kapitalisasi marang pendapatan|OS Therapies (OSTX) - Rasio rega marang pendapatan|Rega marang dodolan radiopharmtheranostics.com (RADX)|Rasio rega marang pendapatan Artiva Biotherapeutics Inc.|Rasio rega marang pendapatan ANL|Rasio rega marang pendapatan Veru Inc. (VERU)|TPST - Rega marang dodolan|Multiplikator P/S XLO (Xilio Therapeutics)|Multiplikator rega marang pendapatan Renovaro Biosciences|MURA: Kapitalisasi marang pendapatan|Rega marang dodolan Kairos Pharma Ltd|OKUR: Multiplikator P/S|Rega marang dodolan CytoMed Therapeutics Limited (GDTC)|Rasio rega marang pendapatan Curis Inc.|Rasio rega marang pendapatan APLM|Multiplikator P/S THAR|ADVB - Rega marang dodolan|Genprex, Inc. - Kapitalisasi marang pendapatan|Calidi Biotherapeutics Inc. - Rasio rega marang pendapatan|Sunshine Biopharma, Inc. - Multiplikator P/S|Xenetic Biosciences (XBIO) - Kapitalisasi marang pendapatan|SLRX: Multiplikator P/S|Kitov Pharma (PPBT) - Multiplikator P/S|Rasio rega marang pendapatan American Oncology Network Inc|Rasio kapitalisasi marang pendapatan BGNE (beigene.com)|Multiplikator P/S CKPT|Kapitalisasi marang pendapatan icadmed.com ICAD|Multiplikator P/S IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Rega marang dodolan|VIRX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MOR (morphosys.com)|NAYA (NAYA Biosciences Inc.) - Kapitalisasi marang pendapatan|Ascentage Pharma Group International - Rasio kapitalisasi pasar marang pendapatan
